Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Cytokinetics Inc (CYTK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Cytokinetics Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while Cytokinetics Inc trades at $84.55 (market cap $11.52B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 3.5× Cytokinetics Inc's market cap, and Cytokinetics Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | CYTK | |
|---|---|---|
Market Cap | $39.89B | $11.52B |
Sector | Health | Technology |
52-Week High | $491.22 | $87.26 |
52-Week Low | $278.09 | $33.23 |
Enterprise Value | $38.15B | $11.99B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Cytokinetics (CYTK) trades at $84.87, down 1.39% today, with a bullish technical signal from moving averages and strong analyst support. The company's recent FDA approval of Myqorzo and European launch drive optimism, though financials show significant losses with a net income margin of -784.02% and negative cash flow from operations of -$510.01 million in 2025. Revenue growth is projected from $88 million to $106 million in 2026, but profitability remains a challenge.
The outlook hinges on Myqorzo's commercial success, with a consensus price target of $110.40 implying 30% upside. Risks include high cash burn, competitive pressures, and reliance on drug adoption. Institutional sentiment is overwhelmingly bullish, but investors must weigh the growth potential against persistent financial losses and execution risks in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →
